New drug trial offers hope for japanese lymphoma patients who have run out of options
NCT ID NCT04542824
Summary
This study is testing a new drug called epcoritamab in Japanese adults with B-cell lymphoma that has come back or stopped responding to standard treatments. The first part of the study aims to find a safe and effective dose. The second part will test that dose, both alone and combined with other standard drugs, to see if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Aichi, Japan
-
Cancer Institute Hospital of JFCR
Tokyo, Japan
-
Fukushima Medical University Hospital
Fukushima, Japan
-
Kagoshima University Hospital
Kagoshima, Japan
-
Kindai University Hospital
Osaka, Japan
-
Kyoto University Hospital
Kyoto, Japan
-
Matsuyama Red Cross Hospital
Ehime, Japan
-
NHO Nagoya Medical Center
Aichi, Japan
-
National Cancer Center Hospital
Tokyo, Japan
-
National Cancer Center Hospital East
Chiba, Japan
-
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
-
Osaka University Hospital
Osaka, Japan
-
Tohoku University Hoaspital
Sendai, Miyagi, 980-8577, Japan
-
Tokyo Medical University Hospital
Tokyo, Japan
-
Yamagata University Hospital
Yamagata, Japan
Conditions
Explore the condition pages connected to this study.